NCT04254107 2025-02-10A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerSeagen Inc.Phase 1 Terminated133 enrolled
NCT01805037 2021-09-01Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasNorthwestern UniversityPhase 1/2 Terminated20 enrolled 17 charts